Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin

This is a preview of subscription content, log in to check access.

References

  1. 1.

    A. S. Avedisova, R. V. Akhankin, V. I. Akhapkina, et al., “Analysis of non-Russian studies of nootropic agents (using piracetam as an example), Ros. Psikhiat. Zh., 1, 57–63 (2001).

    Google Scholar 

  2. 2.

    G. Ya. Avrutskii and A. I. Niss, Pharmacology of the Nootropes (Experimental and Clinical Studies) [in Russian], Moscow (1989), pp. 112–118.

  3. 3.

    Yu. A. Aleksandrovskii, G. M. Rudenko, G. G. Neznamov, et al., A Unified System for Evaluating the Clinical-Pharmacological Actions of Psychotropic Agents in Patients with Borderline Neuropsychiatric Disorders [in Russian], Moscow (1984).

  4. 4.

    Yu. A. Aleksandrovskii, Psychopharmacotherapy [in Russian], Moscow (2005).

  5. 5.

    A. V. Valdman and T. A. Voronina, Pharmacology of the Nootropes (Experimental and Clinical Studies). Collected Studies [in Russian], Moscow (1989).

  6. 6.

    T. A. Voronina and S. B. Seredenin, “Nootropic agents, advances and new problems,” Éksperim. Klin. Farmakol., 61, No. 4, 3–9 (1998).

    CAS  Google Scholar 

  7. 7.

    S. I. Gavrilova, The Pharmacotherapy of Alzheimer's Disease [in Russian], Puls, Moscow (2003).

    Google Scholar 

  8. 8.

    G. Glants, Medical and Biological Statistics [Russian translation from English], Moscow (1999).

  9. 9.

    T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, et al., “Peptide analogs of piracetam as ligands of presumptive nootrope receptors,” Khim.-Farm. Zh., 11, 1322–1329 (1985).

    Google Scholar 

  10. 10.

    I. V. Lamulin, Mild Cognitive Impairments. Methodological Guidelines for Doctors [in Russian], RKI Severo Press, Moscow (2004).

    Google Scholar 

  11. 11.

    V. V. Zakharov and N. N. Yakhno, Memory Disorders, GEOTARMED, Moscow (2003).

  12. 12.

    Ya. B. Kalyn', Mental Health of the Population of Elderly and Aged People (A Clinical-Epidemiological Study) [in Russian], Author's Abstract of Doctoral Thesis in Medical Sciences, Moscow (2001).

  13. 13.

    G. V. Kovalev, Nootropic Substances [in Russian], Volgograd (1990).

  14. 14.

    O. S. Levin, “Diagnosis and treatment of moderate cognitive impairments in the elderly,” Zh. Nevrol. Psikhiat., 8, 42–49 (2006).

    Google Scholar 

  15. 15.

    International Statistical Classification of Diseases and Health-Related Problems (ICD-10) [Russian translation], WHO, Geneva (1995).

  16. 16.

    S. N. Mosolov, Basic Psychopharmacology [in Russian], Vostok, Moscow (1996).

    Google Scholar 

  17. 17.

    G. G. Neznamov, S. A. Syunyakov, I. A. Davydova, and E. S. Teleshova, “The ‘fast’ and 'slow’ components of the psychotropic actions of agents with nootropic properties,” Zh. Nevrol. Psikhiat., 100, No. 6, 33–37 (2000).

    CAS  Google Scholar 

  18. 18.

    G. G. Neznamov, E. S. Teleshova, S. A. Syunyakov, et al., “Treatment of mental disorders in neurology. Clinical studies of the new peptide agent Noopept in patients with psychoorganic disorders,” Consilium Medicum (Neurology/Mental Disorders), 9, No. 2, 10–15 (2007).

    Google Scholar 

  19. 19.

    R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, and S. B. Seredenin, “The original nootropic and neuroprotective dipeptide Noopept (GVS-111),” Éksper. Klin. Farmakol., 65, No. 5, 66–72 (2002).

    CAS  Google Scholar 

  20. 20.

    S. A. Piyavskii, Numerical Decision-Taking Methods in Computerized Methods in Technical Creativity in Construction [in Russian], ASV, Moscow (1994).

    Google Scholar 

  21. 21.

    Handbook of Psychiatry [in Russian], A. S. Tiganov (ed.), Meditsina, Moscow (1999), Vol. 2.

    Google Scholar 

  22. 22.

    V. I. Sergienko and I. B. Bondareva, Mathematical Statistics in Clinical Trials [in Russian], Moscow (2001).

  23. 23.

    A. A. Skoromets, Neurotransmitters in Brain Aging: the Key to Understanding Memory and Attention Disorders [in Russian], Moscow (2005).

  24. 24.

    E. Arnaiz and O. Almkvist, “Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease,” Acta Neurol. Scand., 107, Supplement 179, 34–41 (2003).

    Article  Google Scholar 

  25. 25.

    D. A. Bennett, “Mild cognitive impairment,” Clin. Geriat. Med., 20, 15–25 (2004).

    Article  Google Scholar 

  26. 26.

    H. Braak, K. Del Tredici, and E. Braak, “Spectrum of pathology,” in: Mild Cognitive Impairment, R. C. Petersen (ed.), Oxford University Press (2003), pp. 149–189.

  27. 27.

    C. E. Coffey, W. E. Wilkinson, I. A. Parashos, et al., “Quantitative cerebral anatomy of the aging human brain,” Neurology, 42, 527–536 (1992).

    PubMed  CAS  Google Scholar 

  28. 28.

    H. C. Comijs, M. G. Dik, D. J. H. Deeg, et al., “The course of cognitive decline in older patients,” Dement. Geriat. Cogn. Dis., 17, 136–142 (2004).

    Article  Google Scholar 

  29. 29.

    E. Daly, D. Zaitchik, M. Copeland, et al., Clinical Predictors of Conversion to Alzheimer's Disease, B. Vellas et al. (eds.), Serdi Publisher, Paris (2001), Vol. 5, pp. 44–49.

    Google Scholar 

  30. 30.

    W. Danysz, C. G. Parsons, H.-J. Mobius, et al., “Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-A unified glutamatergic hypothesis on the mechanism of action,” Neurotox. Res., 2, 85–97 (2000).

    PubMed  CAS  Article  Google Scholar 

  31. 31.

    D. De Wied, Neurochemical and Psychopharmacological Approaches to Cognitive Entracers, Kyoto (1995).

  32. 32.

    M. F. Folstein, S. E. Folstein, and P. R. McHugh, J. Psychiat. Res., 12, No. 3, 189–198 (1975).

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    C. Giurgea, “Vers une pharmacologie de l'activite integrative du cerveau. Tentative du concept nootrop en psychopharmacologie,” Actual Pharmacol., 25, 115–157 (1972).

    CAS  Google Scholar 

  34. 34.

    T. Gudasheva, T. Voronina, R. Ostrovskaya, et al., “Synthesis and antiamnestic activity of a series of N-acylprolyl-containing dipeptides,” Eur. J. Med. Chem., 31, 151–157 (1996).

    Article  CAS  Google Scholar 

  35. 35.

    J. W. Jacobs, M. R. Bernhard, F. Delgado, and J. J. Strain, Ann. Int. Med., 86, 40–46 (1977).

    PubMed  CAS  Google Scholar 

  36. 36.

    D. S. Knopman, B. F. Boeve, and R. C. Petersen, “Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia,” Mayo Clinic Proc., 78, 1290–1308 (2003).

    Article  Google Scholar 

  37. 37.

    National Institute of Mental Health, 12-CGI. Clinical Global Impression, W. Guyo (ed.), ECDEU Assessment Manual for Psychopharmacology, Rockville, Maryland (1976), 217–222.

    Google Scholar 

  38. 38.

    R. Ostrovskaya et al., Anxiolytic Activity of Nootropic Dipeptide Noopept, Nova Sci. Publ. (2006), Vol. 10, pp. 1–10.

    Google Scholar 

  39. 39.

    K. Palmer, L. Backman, B. Winblad, and L. Fratiglioni, “Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study,” Brit. Med. J., 326, 245–249 (2003).

    PubMed  Article  Google Scholar 

  40. 40.

    R. S. Petersen, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, 303–308 (1999).

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    R. S. Petersen, “Mild cognitive impairment: transition from aging to Alzheimer's disease,” in: Advances of Etiology, Pathogenesis, and Therapeutics, K. Igbal et al. (eds.), Wiley, Chichester, etc. (2001), pp. 140–151.

    Google Scholar 

  42. 42.

    B. Reisberg, S. H. Ferris, et al., Psychopharm. Bull., 19, 47–50 (1983).

    Google Scholar 

  43. 43.

    K. Ritchie, S. Artero, and J. Touchon, “Classification criteria for mild cognitive impairment. A population-based validation study,” Neurology, 56, 37–42 (2001).

    PubMed  CAS  Google Scholar 

  44. 44.

    S. Seredenin, T. Voronina, T. Gudasheva, R. Ostrovskaya, et al., “Biologically active N-acylprolyldipeptides having antiamnestic, antihypoxic, and anorexigenic effects,” US Patent No. 5439930 (1995).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to G. G. Neznamov.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 108, No. 3, pp. 33–42, March, 2008.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Neznamov, G.G., Teleshova, E.S. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physi 39, 311 (2009). https://doi.org/10.1007/s11055-009-9128-4

Download citation

Keywords

  • Mild Cognitive Impairment
  • Mini Mental State Examination
  • Daytime Drowsiness
  • Piracetam
  • Mini Mental State Examination Score